UNSPSC 51332507: Cloroperone

This classification denotes an anxiolytic with the molecular formula C22H23CLFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 948IHI495K chemically known as 1-butanone, 4-(4-(4-chlorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as cloroperone, which bears US NIH Compound Identifier 41536. European Medicines Agency schedules Cloroperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06763MIG.

UNSPSC 51332507 Cloroperone is a Commodity code that does not align with the recent state and local contract opportunities tagged under it. The three opportunities on record involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which involve cloroperone, a chemical intermediate used in pharmaceutical synthesis. The mismatch suggests this code either sees minimal relevant state and local procurement activity or has been misapplied to unrelated health-sector procurements in available databases.

The three recent opportunities span health agencies and cooperative purchasing vehicles across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems to support community health initiatives with quarterly deliveries and fixed-fee pricing. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer pharmacy initiative outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, requiring vendors to work through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance. No active procurement under the cloroperone code itself is evident.